Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs58542926
rs58542926
0.100 GeneticVariation BEFREE CC genotype of TM6SF2 rs58542926 was associated with a significantly lower risk of NAFLD, while MBOAT7 rs641738 was not related to NAFLD risks. 30824369

2019

dbSNP: rs58542926
rs58542926
0.100 GeneticVariation BEFREE The rs738409 single nucleotide polymorphism (SNP) in patatin-like phospholipase domain-containing protein 3 gene and the rs58542926 SNP in transmembrane 6 superfamily member 2 gene have been robustly associated with NAFLD and with its progression, but promising results have been obtained with many other SNPs. 30487694

2018

dbSNP: rs58542926
rs58542926
0.100 GeneticVariation BEFREE Here, we accessed the seven polymorphisms of rs1260326, rs780094 in GCKR, rs2954021 near TRIB1, rs2228603 in NCAN, rs58542926 in TM6SF2, rs12137855 near LYPLAL1, and rs10883437 near CPN1 on NAFLD susceptibility in the Uygur population. 30646922

2019

dbSNP: rs58542926
rs58542926
0.100 GeneticVariation BEFREE Interestingly, patients harbouring the TM6SF2 rs58542926 T allele that predispose to NAFLD/NASH had higher LBP level. 28464257

2017

dbSNP: rs58542926
rs58542926
0.100 GeneticVariation BEFREE Metabolic syndrome (MetS) and genetic polymorphisms PNPLA3 rs738409, TM6SF2 rs585</span>42926 and MBOAT7 rs641738 are known inductors of non-alcoholic fatty liver disease (NAFLD). 31851849

2019

dbSNP: rs58542926
rs58542926
0.100 GeneticVariation BEFREE The rs58542926 SNP in the TM6SF2 gene is associated with pediatric nonalcoholic fatty liver disease but may confer protection against cardiovascular risk. 26457389

2016

dbSNP: rs58542926
rs58542926
0.100 GeneticVariation BEFREE The PNPLA3 mutation as well as the novel NAFLD-predisposing genetic variant (TM6SF2 p.E167K) were genotyped with allele-specific probes. 26264356

2016

dbSNP: rs58542926
rs58542926
0.100 GeneticVariation BEFREE Importantly, our data indicates that the genetic variant TM6SF2 E167K, previously associated with increased risk for NAFLD, induces increased hepatocyte fat content by reducing APOB particle secretion. 31406127

2019

dbSNP: rs58542926
rs58542926
0.100 GeneticVariation BEFREE Because PNPLA3 rs738409, GCKR rs780094 and TM6SF2 rs58542926 variants are known to confer susceptibility to NAFLD, we assessed the influence of MBOAT7 rs641738 on hepatic steatosis, and serum levels of CK-18 fragment (a biomarker of hepatocellular injury and apoptosis for NAFLD) after adjusting the effects of PNPLA3, GCKR and TM6SF2 polymorphisms. 29314568

2018

dbSNP: rs58542926
rs58542926
0.100 GeneticVariation BEFREE rs58542926 is a low-frequency variant with a modest effect on NAFLD, suggesting that carriers of the T allele are slightly more likely to accumulate fat in the liver and develop nonalcoholic steatohepatitis than those without. 25302781

2015

dbSNP: rs58542926
rs58542926
0.100 GeneticVariation BEFREE The TM6SF2 rs58542926 T allele promotes the abnormal regulation of lipid profiles and liver injury in NA</span>FLD patients, NAFLD&CRA patients, and overall subjects. 30727943

2019

dbSNP: rs58542926
rs58542926
0.100 GeneticVariation BEFREE An I148 M variant in patatin-like phospholipase domain-containing protein 3 (PNPLA3) and an E167K variant in transmembrane 6 superfamily 2 (TM6SF2) are major genetic risk factors for the development and progression of NAFLD. 30550414

2019

dbSNP: rs58542926
rs58542926
0.100 GeneticVariation BEFREE However, it was found that a one-portion increase in fish intake increased the risk of NAFLD in carriers of the risk allele of TM6SF2 rs58542926 polymorphism compared to non-carriers, after adjusting for age, gender, energy intake, pack-years, PAL, TM6SF2 genotype and fish consumption (OR<sub>dominant</sub> = 1.503, 95% CI 1.094-2.064). 29574608

2019

dbSNP: rs58542926
rs58542926
0.100 GeneticVariation BEFREE Combining the I148M and E167K variants in a manner of an additive effect could improve risk prediction for NAFLD in a Qingdao Han Population cohort. 30738435

2019

dbSNP: rs58542926
rs58542926
0.100 GeneticVariation BEFREE Genomic studies confirmed that PNPLA3 I148M and TM6SF2 E167K polymorphisms affected NAFLD susceptibility in the general population. 26379412

2015

dbSNP: rs58542926
rs58542926
0.100 GeneticVariation BEFREE This study confirmed the genetic association of missense SNP of TM6SF2, rs58542926, with plasma lipid levels in multiple East Asian ethnic groups and with NAFLD in Japanese individuals. 26758378

2016

dbSNP: rs58542926
rs58542926
0.100 GeneticVariation BEFREE The TM6SF2 E167K variant was associated with NAFLD in northeast China, and there was an interaction between the PNPLA3 I148M and TMS6F2 E167K variants in NAFLD. 31054977

2020

dbSNP: rs58542926
rs58542926
0.100 GeneticVariation BEFREE TM6SF2 rs58542926 variant affects postprandial lipoprotein metabolism and glucose homeostasis in NAFLD. 28242789

2017

dbSNP: rs58542926
rs58542926
0.100 GeneticVariation BEFREE The adiponutrin (PNPLA3) p.I148M and transmembrane 6 superfamily member 2 (TM6SF2) p.E167K variants represent risk factors for non-alcoholic fatty liver disease (NAFLD). 26745555

2016

dbSNP: rs58542926
rs58542926
0.100 GeneticVariation BEFREE Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study. 27836992

2017

dbSNP: rs58542926
rs58542926
0.100 GeneticVariation BEFREE Among individual variants, rs1260326 in GCKR and rs641738 in MBOAT7 (recessive), rs58542926 in TM6SF2 and rs738409 in PNPLA3 (dominant) emerged as associated to NAFLD, with PNPLA3 rs738409 being the strongest predictor (OR 3.12, 95% CI, 1.8-5.5, P < 0.001). 29487372

2018

dbSNP: rs58542926
rs58542926
0.100 GeneticVariation BEFREE TM6SF2 rs58542926 is clearly associated with NAFLD, but it is not clearly associated with HCC. 26493626

2016

dbSNP: rs58542926
rs58542926
0.100 GeneticVariation BEFREE As variants in PNPLA3 (I148M) and TM6SF2 (E167K) are associated with nonalcoholic fatty liver disease, we assessed these variants in type 2 diabetes (T2D) patients randomized to receive BIL (n=1822) or GL (n=1270) in three phase 3 trials. 29160303

2018

dbSNP: rs58542926
rs58542926
0.100 GeneticVariation BEFREE There was no significant difference in the proportions of patients with rs738409 C>G in PNPLA3, but a significantly greater proportion of patients with lean NAFLD carried rs58542926 C>T in TM6SF2 (4%) than obese or overweight individuals with NAFLD (0.3%; P = .001). 28554682

2017

dbSNP: rs58542926
rs58542926
0.100 GeneticVariation BEFREE The rs58542926 T allele had no effect on inflammation, impacted ≥F2 fibrosis in CHC and NAFLD assessed cross-sectionally (odds ratio = 1.39, 95% confidence interval 1.04-1.87, and odds ratio = 1.62, 95% confidence interval 1.03-2.52, respectively; P < 0.03 for both), but had no effect on fibrosis progression in 1174 patients with CHC and a known duration of infection. 26822232

2016